Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Drug Development Guidances: Oncology, Diabetes, Obesity Are Priorities

Executive Summary

FDA's top priorities for drug development guidances are in the areas of oncology, diabetes and obesity

You may also be interested in...



Diabetes Draft Guidance May Require Extended Trial Length, Participation

A long-awaited diabetes draft guidance from FDA may result in longer and larger clinical trials, but does not significantly alter the development landscape since it re-affirms the agency's faith in a long-used surrogate marker and the technique of post-market outcomes assessment

Diabetes Draft Guidance May Require Extended Trial Length, Participation

A long-awaited diabetes draft guidance from FDA may result in longer and larger clinical trials, but does not significantly alter the development landscape since it re-affirms the agency's faith in a long-used surrogate marker and the technique of post-market outcomes assessment

FDA/NIH diabetes public meeting

FDA and National Institutes of Health will hold a joint public meeting May 13 and 14 to discuss the treatment of type 1 and type 2 diabetes mellitus. The FDA/NIH collaboration is part of Commissioner McClellan's strategic plan to develop a regulatory framework that would encourage the development of treatments in high-need areas, such as diabetes, cancer, obesity and lupus (1"The Pink Sheet" Feb. 10, 2003, p. 5)...

Related Content

Latest News
See All
UsernamePublicRestriction

Register

PS041238

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel